Non-Invasive Pre-Natal Testing (NIPT) has the potential of bringing safer pregnancy testing to the wider NHS, but not without its challenges.
Efficiently translating genomic research into the clinic is one of the most important steps in the development of the field. The clinic is where we will see things come to fruition.
The US Health and Human Services Secretary Alex Azar has approved adding a test for spinal muscular atrophy to the list of recommended newborn screens in the United States.
Phenotyping trailblazers are proving an impressive success in the clinic as the continue to go from strength to strength.
People living in England will be the first in the world to have access to DNA tests as routine care starting this fall, putting the NHS at the forefront of healthcare, as it takes a huge step towards precision medicine.
As the NHS celebrates its 70th birthday, Genomics England announces that it has now passed the 70,000 genomes mark.
The “Born in Guangzhou Cohort Study” is looking to recruit 50,000 baby-mother sets by 2020. Since 2012, 1.6 million samples have been collected for the project and the some of the first findings have been published.
Cancer Research UK Cambridge Institute is pushing for the use of genetic testing to transform treatment of breast cancer with the Personalised Breast Cancer Programme.
European genetics blockchain company, DNAtix, have announced the pilot of their blockchain-based infrastructure and ecosystem for genetic testing, services and research.
Researchers have created nanoparticles that can zap tumours with significant amounts of heat under a low magnetic field.
The Large Scale Genomics Work Stream of the GA4GH has announced 8 new implementations of its htsget protocol, a standard for accessing large-scale genomic sequencing data online without using file transfers.
Psychiatric disorders share many genetic variants, while neurological disorders appear more distinct, according to a new study from the Brainstorm Consortium.
A survey of people who have taken part in clinical trials indicates that participants care more about the benefits to science than the risk of sharing their personal data.